Results 51 to 60 of about 3,249,675 (219)

The Role of Ranolazine in the Treatment of Ventricular Tachycardia and Atrial Fibrillation: A Narrative Review of the Clinical Evidence

Biomedicines
Cardiac arrhythmias are among the leading causes of morbidity and mortality worldwide. While antiarrhythmic drugs traditionally represent the first-line management strategy, their use is often limited by profound proarrhythmic effects.
Kyosuke Murai, Amir Vasigh, Tamás Alexy, Kálmán Tóth, László Czopf   +4 more
doaj   +1 more source

Pharmacological Treatment for Atrial Fibrillation

Journal of Arrhythmia, 2005
Pharmacological treatment for atrial fibrillation has a variety of purposes, such as pharmacological defibrillation, maintenance of sinus rhythm, heart rate control to prevent congestive heart failure and prevention of both cerebral infarction and atrial
Kaoru Sugi, MD PhD, Mahito Noro, MD PhD, Takao Sakata, MD PhD, Naoki Tezuka, MD, Takeshi Nakae, MD, Kenta Kumagai, MD, Tsuyoshi Sakai, MD PhD, Ayaka Numata, MD PhD, Hidetoshi Itakura, MD, Akiyoshi Moriyama, MD, Shingo Kujime, MD   +10 more
doaj   +1 more source

Dexmedetomidine sedation reduces the incidence of atrial fibrillation in mechanically ventilated patients with COVID-19 pneumonia: A randomized controlled trial

Egyptian Journal of Anaesthesia, 2023
Background Atrial fibrillation (AF) is a cardiac complication commonly associated with COVID-19 infection, especially in severe cases. The sedative agent dexmedetomidine is known to cause bradycardia. In this study, we are testing whether dexmedetomidine
Ahmed Mohamed Fetouh, Motaz Amr Abu Sabaa, Ahmed Fekry Aboelezz, Amr Arafa Elbadry   +3 more
doaj   +1 more source

Connecting the dots: A narrative review of the relationship between heart failure and cognitive impairment

ESC Heart Failure, Volume 12, Issue 2, Page 1119-1131, April 2025.
Abstract Large clinical data underscore that heart failure is independently associated to an increased risk of negative cognitive outcome and dementia. Emerging evidence suggests that cerebral hypoperfusion, stemming from reduced cardiac output and vascular pathology, may contribute to the largely overlapping vascular dementia and Alzheimer's disease ...
Mauro Massussi, Maria Giulia Bellicini, Marianna Adamo, Andrea Pilotto, Marco Metra, Alessandro Padovani, Riccardo Proietti   +6 more
wiley   +1 more source

Role of pharmacotherapy in Brugada syndrome [PDF]

, 2004
In patients who undergo aborted sudden cardiac death or syncope of unknown origin (symptomatic Brugada syndrome), no one argues that the implantation of an ICD is the first-line therapy regardless of the findings of the EP study.
Tsuchiya, Takeshi
core   +1 more source

Clinical study of Russian class III antiarrhythmic agent, nibentan, in supraventricular arrhythmia management

Кардиоваскулярная терапия и профилактика, 2005
Aim. To study clinical efficacy of a new, class III, antiarrhythmic agent, nibentan, in various supraventricular (SV) cardiac arrythmias. Material and methods.
V. G. Valiev, A. E. Radzevich, V. A. Gorshkov, E. M. Zeltyn, A. B. Besprozvanny, E. N. Ostroumov   +5 more
doaj  

Heart failure in patients with a systemic right ventricle: A multicentre study with long‐term follow‐up

European Journal of Heart Failure, EarlyView.
Risk of heart failure hospitalization in patients with a systemic right ventricle. AF, atrial fibrillation; AtrSO, atrial switch operation; ccTGA, congenitally corrected transposition of the great arteries; D‐TGA, dextro‐transposition of the great arteries; ECG, electrocardiogram; HF, heart failure; HR, hazard ratio; NYHA, New York Heart Association ...
Mohammad Mostafa Ansari Ramandi, Werner Budts, Jolien W. Roos‐Hesselink, Willem A. Helbing, Anastasia D. Egorova, Berto J. Bouma, Anthonie Duijnhouwer, Roland van Kimmenade, Gertjan T. Sieswerda, Thelma C. Konings, Lodewijk J. Wagenaar, Joey F.A. Ubachs, Rolf M.F. Berger, Elke S. Hoendermis, Adriaan A. Voors, Joost P. van Melle   +15 more
wiley   +1 more source

Facilitation of I Kr current by some hERG channel blockers suppresses early afterdepolarizations. [PDF]

, 2019
Drug-induced block of the cardiac rapid delayed rectifying potassium current (I Kr), carried by the human ether-a-go-go-related gene (hERG) channel, is the most common cause of acquired long QT syndrome.
Chen, I-Shan, Furutani, Kazuharu, Handa, Kenichiro, Kurachi, Yoshihisa, Sack, Jon T, Tsumoto, Kunichika, Yamakawa, Yuko   +6 more
core   +1 more source

Effects of a Novel Cyclohexane Dicarboximide Derivative, ST-6, on Reperfusion-Induced Arrhythmia in Rats

Journal of Pharmacological Sciences, 2005
The present study was designed to determine whether a novel cyclohexane dicarboximide derivative, ST-6, 2-[4-[4-(chlorophenyl)-4-hydroxy-1-piperidinyl]butyl]hexahydro-1H-isoindol-1,3(2H)-dione, prevents reperfusion-induced ventricular arrhythmias ...
Hiroshi Kajiwara, Itaru Ohoi, Kouichi Tanonaka, Satoshi Takeo   +3 more
doaj   +1 more source

European Journal of Heart Failure consensus statement. Heart failure pharmacotherapy for patients with heart failure with reduced ejection fraction and concomitant atrial fibrillation: Review of evidence and call to action

European Journal of Heart Failure, EarlyView.
Heart failure (HF) and atrial fibrillation (AF) are major global health challenges with rising prevalence and significant morbidity, mortality, and healthcare burden. Despite advances in HF management, AF remains a critical comorbidity that worsens outcomes and requires ad hoc treatment strategies, increasing the risk of non‐adherence and side effects.
Mark Luedde, Stefan Agewall, Giuseppe Ambrosio, Antoni Bayes‐Genis, Claudio Borghi, Elisabetta Cerbai, Gheorghe A. Dan, Heinz Drexel, Péter Ferdinandy, Erik Lerkevang Grove, Juan Carlos Kaski, Roland Klingenberg, Joao Morais, William Parker, Mark C. Petrie, Bianca Rocca, Anne Grete Semb, Michele Senni, Christian Sohns, Patrick Sulzgruber, Juan Tamargo, Marco Metra, Michael Böhm, Dobromir Dobrev, Samuel Sossalla   +24 more
wiley   +1 more source